Locations:
Search
Patient achieves complete remission from aggressive marginal zone lymphoma with liso-cel
Patient with TP53 mutation achieves full response with targeted therapy
Concurrent treatment necessary for addressing progressive disease and infection
Preliminary results suggest combination therapy with lisaftoclax improves survival with few adverse events in patients with AL amyloidosis and relapsed/refractory multiple myeloma
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
New system refines classification of cytogenetic abnormalities at time of response assessment and their clinical significance
Lifetime Achievement award-winner reflects on psychosocial support and caregiver readiness
Questions remain about the merits of asparaginase-based therapy
Phase 1 study found mutant calreticulin-specific monoclonal antibody brings promising results with no dose-limiting toxicities
Age alone should not rule out patients from potentially curative treatment
Discussing research into improving CAR T-cell therapy efficacy
Advertisement
Advertisement